Bart P C Van De Warrenburg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9293995/publications.pdf

Version: 2024-02-01

220 papers

11,355 citations

23500 58 h-index 95 g-index

226 all docs

226
docs citations

226 times ranked 13800 citing authors

#	Article	IF	CITATIONS
1	Human Induced Pluripotent Stem Cell-Based Modelling of Spinocerebellar Ataxias. Stem Cell Reviews and Reports, 2022, 18, 441-456.	1.7	7
2	Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, 267-282.	1.5	21
3	Characterization of Lifestyle in Spinocerebellar Ataxia Type 3 and Association with Disease Severity. Movement Disorders, 2022, 37, 405-410.	2.2	8
4	The complexities of CACNA1A in clinical neurogenetics. Journal of Neurology, 2022, 269, 3094-3108.	1.8	16
5	Increased trunk movements in people with hereditary spastic paraplegia: do these involve balance correcting strategies?. Journal of Neurology, 2022, , 1.	1.8	2
6	Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force – An Update. Movement Disorders, 2022, 37, 905-935.	2.2	49
7	How to proceed after "negative―exome: A review on genetic diagnostics, limitations, challenges, and emerging new multiomics techniques. Journal of Inherited Metabolic Disease, 2022, 45, 663-681.	1.7	20
8	Cerebellar Transcranial Direct Current Stimulation in Spinocerebellar Ataxia Type 3: a Randomized, Double-Blind, Sham-Controlled Trial. Neurotherapeutics, 2022, 19, 1259-1272.	2.1	21
9	Cerebellar transcranial direct current stimulation modulates timing but not acquisition of conditioned eyeblink responses in SCA3 patients. Brain Stimulation, 2022, 15, 806-813.	0.7	7
10	Differential Temporal Dynamics of Axial and Appendicular Ataxia in <scp>SCA3</scp> . Movement Disorders, 2022, 37, 1850-1860.	2.2	11
11	A word of hope for ataxia trials in COVID-19 time and beyond. Journal of Neurology, 2021, 268, 2343-2345.	1.8	3
12	Differences in the Presentation and Progression of Parkinson's Disease by Sex. Movement Disorders, 2021, 36, 106-117.	2.2	54
13	Endocrine and Growth Abnormalities in 4H Leukodystrophy Caused by Variants in <i>POLR3A</i> , <i>POLR3B</i> , and <i>POLR1C</i> , Journal of Clinical Endocrinology and Metabolism, 2021, 106, e660-e674.	1.8	26
14	<scp>Myoclonusâ€Ataxia</scp> Syndromes: A Diagnostic Approach. Movement Disorders Clinical Practice, 2021, 8, 9-24.	0.8	11
15	Improving gait adaptability in patients with hereditary spastic paraplegia (Move-HSP): study protocol for a randomized controlled trial. Trials, 2021, 22, 32.	0.7	7
16	The Dutch Yips Study: Results of a Survey Among Golfers. Tremor and Other Hyperkinetic Movements, 2021, 11, 27.	1.1	2
17	The Architecture of Contemporary Care Networks for Rare Movement Disorders: Leveraging the ParkinsonNet Experience. Frontiers in Neurology, 2021, 12, 638853.	1.1	4
18	Inverse associations between cerebellar inhibition and motor impairment in spinocerebellar ataxia type 3. Brain Stimulation, 2021, 14, 351-357.	0.7	12

#	Article	IF	CITATIONS
19	The cerebellar cognitive affective syndrome scale reveals early neuropsychological deficits in SCA3 patients. Journal of Neurology, 2021, 268, 3456-3466.	1.8	32
20	Discordance Between Patient-Reported Outcomes and Physician-Rated Motor Symptom Severity in Early-to-Middle-Stage Spinocerebellar Ataxia Type 3. Cerebellum, 2021, 20, 887-895.	1.4	12
21	Biallelic loss-of-function variations in PRDX3 cause cerebellar ataxia. Brain, 2021, 144, 1467-1481.	3.7	18
22	Family history as a clue to the diagnosis of orofacial movements in a 30-year-old man: Expert commentary. Parkinsonism and Related Disorders, 2021, 85, 149-150.	1.1	0
23	Biallelic variants in <i>HPDL</i> cause pure and complicated hereditary spastic paraplegia. Brain, 2021, 144, 1422-1434.	3.7	22
24	The ARCA Registry: A Collaborative Global Platform for Advancing Trial Readiness in Autosomal Recessive Cerebellar Ataxias. Frontiers in Neurology, 2021, 12, 677551.	1.1	15
25	Healthcare needs, expectations, utilization, and experienced treatment effects in patients with hereditary spastic paraplegia: a web-based survey in the Netherlands. Orphanet Journal of Rare Diseases, 2021, 16, 283.	1.2	4
26	Natural History of Polymerase Gamma–Related Ataxia. Movement Disorders, 2021, 36, 2642-2652.	2.2	10
27	Nicotinamide Riboside Improves Ataxia Scores and Immunoglobulin Levels in Ataxia Telangiectasia. Movement Disorders, 2021, 36, 2951-2957.	2.2	18
28	Spinocerebellar ataxias in Asia: Prevalence, phenotypes and management. Parkinsonism and Related Disorders, 2021, 92, 112-118.	1.1	9
29	KIF1A variants are a frequent cause of autosomal dominant hereditary spastic paraplegia. European Journal of Human Genetics, 2020, 28, 40-49.	1.4	65
30	The Role of the Cerebellum in Degenerative Ataxias and Essential Tremor: Insights From Noninvasive Modulation of Cerebellar Activity. Movement Disorders, 2020, 35, 215-227.	2.2	45
31	Classic ataxia-telangiectasia: the phenotype of long-term survivors. Journal of Neurology, 2020, 267, 830-837.	1.8	14
32	A hereditary spastic paraplegia predominant phenotype caused by variants in the NEFL gene. Parkinsonism and Related Disorders, 2020, 80, 98-101.	1.1	4
33	Reply: A homozygous GDAP2 loss-of-function variant in a patient with adult-onset cerebellar ataxia; and Novel GDAP2 pathogenic variants cause autosomal recessive spinocerebellar ataxia-27 (SCAR27) in a Chinese family. Brain, 2020, 143, e51-e51.	3.7	1
34	De novo variants in CAMTA1 cause a syndrome variably associated with spasticity, ataxia, and intellectual disability. European Journal of Human Genetics, 2020, 28, 763-769.	1.4	7
35	Experienced complaints, activity limitations and loss of motor capacities in patients with pure hereditary spastic paraplegia: a web-based survey in the Netherlands. Orphanet Journal of Rare Diseases, 2020, 15, 64.	1.2	13
36	COVID-19 reveals influence of physical activity on symptom severity in hereditary spastic paraplegia. Journal of Neurology, 2020, 267, 3462-3464.	1.8	7

#	Article	IF	CITATIONS
37	Autosomal dominant GCH1 mutations causing spastic paraplegia at disease onset. Parkinsonism and Related Disorders, 2020, 74, 12-15.	1.1	11
38	Clinicoâ€Genetic, Imaging and Molecular Delineation of <scp><i>COQ8A</i></scp> â€Ataxia: A Multicenter Study of 59 Patients. Annals of Neurology, 2020, 88, 251-263.	2.8	52
39	Diagnosis and Management of Ataxia-Telangiectasia in Resource-Limited Settings. Journal of International Child Neurology Association, 2020, $1,\dots$	0.0	1
40	Genotype, extrapyramidal features, and severity of variant ataxiaâ€ŧelangiectasia. Annals of Neurology, 2019, 85, 170-180.	2.8	58
41	Movement disorders in cerebrotendinous xanthomatosis. Parkinsonism and Related Disorders, 2019, 58, 12-16.	1.1	42
42	Cerebellar transcranial direct current stimulation in spinocerebellar ataxia type 3 (SCA3-tDCS): rationale and protocol of a randomized, double-blind, sham-controlled study. BMC Neurology, 2019, 19, 149.	0.8	20
43	Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. Movement Disorders, 2019, 34, 1839-1850.	2.2	122
44	Integrative network and brain expression analysis reveals mechanistic modules in ataxia. Journal of Medical Genetics, 2019, 56, 283-292.	1.5	15
45	Prediction of Survival With Longâ€∓erm Disease Progression in Most Common Spinocerebellar Ataxia. Movement Disorders, 2019, 34, 1220-1227.	2.2	14
46	Network localization of cervical dystonia based on causal brain lesions. Brain, 2019, 142, 1660-1674.	3.7	160
47	Functional effects of botulinum toxin type A in the hip adductors and subsequent stretching in patients with hereditary spastic paraplegia. Journal of Rehabilitation Medicine, 2019, 51, 434-441.	0.8	14
48	Genotype–phenotype correlations in ataxia telangiectasia patients with ⟨i⟩ATM⟨ i⟩ c.3576G>A and c.8147T>C mutations. Journal of Medical Genetics, 2019, 56, 308-316.	1.5	29
49	The Shaking Shoelace. Journal of Parkinson's Disease, 2019, 9, 249-250.	1.5	1
50	Billiards-related dystonia: A new task-specific dystonia. Parkinsonism and Related Disorders, 2019, 60, 10-11.	1.1	9
51	"Ears of the Lynx―MRI Sign Is Associated with SPG11 and SPG15 Hereditary Spastic Paraplegia. American Journal of Neuroradiology, 2019, 40, 199-203.	1.2	50
52	Abnormal eyeblink conditioning is an early marker of cerebellar dysfunction in preclinical SCA3 mutation carriers. Experimental Brain Research, 2019, 237, 427-433.	0.7	15
53	The movement disorder spectrum of SCA21 (ATX-TMEM240): 3 novel families and systematic review of the literature. Parkinsonism and Related Disorders, 2019, 62, 215-220.	1.1	18
54	Mutations in <i>VPS13D</i> lead to a new recessive ataxia with spasticity and mitochondrial defects. Annals of Neurology, 2018, 83, 1075-1088.	2.8	122

#	Article	IF	CITATIONS
55	Author response: <scp>l</scp> -Dopa in dystonia: A modern perspective. Neurology, 2018, 90, 47-47.	1.5	O
56	Survival in patients with spinocerebellar ataxia types 1, 2, 3, and 6 (EUROSCA): a longitudinal cohort study. Lancet Neurology, The, 2018, 17, 327-334.	4.9	69
57	SnapShot: Biology of Genetic Ataxias. Cell, 2018, 175, 890-890.e1.	13.5	3
58	StartReact during gait initiation reveals differential control of muscle activation and inhibition in patients with corticospinal degeneration. Journal of Neurology, 2018, 265, 2531-2539.	1.8	13
59	The genetic nomenclature of recessive cerebellar ataxias. Movement Disorders, 2018, 33, 1056-1076.	2.2	61
60	Long-term evolution of patient-reported outcome measures in spinocerebellar ataxias. Journal of Neurology, 2018, 265, 2040-2051.	1.8	34
61	GDAP2 mutations implicate susceptibility to cellular stress in a new form of cerebellar ataxia. Brain, 2018, 141, 2592-2604.	3.7	19
62	The patchy tremor landscape: recent advances in pathophysiology. Current Opinion in Neurology, 2018, 31, 455-461.	1.8	35
63	A homozygous <i>FITM2</i> mutation causes a deafness-dystonia syndrome with motor regression and signs of ichthyosis and sensory neuropathy. DMM Disease Models and Mechanisms, 2017, 10, 105-118.	1.2	16
64	Ataxia-telangiectasia: Immunodeficiency and survival. Clinical Immunology, 2017, 178, 45-55.	1.4	72
65	Effects of acetyl-DL-leucine on cerebellar ataxia (ALCAT trial): study protocol for a multicenter, multinational, randomized, double-blind, placebo-controlled, crossover phase III trial. BMC Neurology, 2017, 17, 7.	0.8	23
66	Ataxiaâ€ŧelangiectasia: recommendations for multidisciplinary treatment. Developmental Medicine and Child Neurology, 2017, 59, 680-689.	1.1	61
67	<scp>I</scp> -Dopa in dystonia. Neurology, 2017, 88, 1865-1871.	1.5	35
68	The clinical heterogeneity of drug-induced myoclonus: an illustrated review. Journal of Neurology, 2017, 264, 1559-1566.	1.8	28
69	Exome sequencing and network analysis identifies shared mechanisms underlying spinocerebellar ataxia. Brain, 2017, 140, 2860-2878.	3.7	98
70	A recessive ataxia diagnosis algorithm for the next generation sequencing era. Annals of Neurology, 2017, 82, 892-899.	2.8	27
71	Body Mass Index Decline Is Related to Spinocerebellar Ataxia Disease Progression. Movement Disorders Clinical Practice, 2017, 4, 689-697.	0.8	25
72	Clinical and genetic characteristics of sporadic adult-onset degenerative ataxia. Neurology, 2017, 89, 1043-1049.	1.5	45

#	Article	IF	Citations
73	High-throughput Analysis of Locomotor Behavior in the Drosophila Island Assay. Journal of Visualized Experiments, 2017, , .	0.2	10
74	Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease. Brain, 2017, 140, 3191-3203.	3.7	323
7 5	Complicated hereditary spastic paraplegia due to ATP13A2 mutations: what's in a name?. Brain, 2017, 140, e73-e73.	3.7	5
76	Pathophysiology, diagnostic work-up and management of balance impairments and falls in patients with hereditary spastic paraplegia. Journal of Rehabilitation Medicine, 2017, 49, 369-377.	0.8	19
77	<scp>N</scp> omenclature of genetic movement disorders: <scp>R</scp> ecommendations of the international <scp>P</scp> arkinson and movement disorder society task force. Movement Disorders, 2016, 31, 436-457.	2.2	228
78	Clinical exome sequencing for cerebellar ataxia and spastic paraplegia uncovers novel gene–disease associations and unanticipated rare disorders. European Journal of Human Genetics, 2016, 24, 1460-1466.	1.4	89
79	The Genetic Homogeneity of CAPOS Syndrome: Four New Patients With the c.2452G>A (p.Glu818Lys) Mutation in the ATP1A3 Gene. Pediatric Neurology, 2016, 59, 71-75.e1.	1.0	35
80	Expanding the phenotype in aminoacylase 1 (ACY1) deficiency: characterization of the molecular defect in a 63-year-old woman with generalized dystonia. Metabolic Brain Disease, 2016, 31, 587-592.	1.4	12
81	The Symptomatic Treatment of Acquired Dystonia: A Systematic Review. Movement Disorders Clinical Practice, 2016, 3, 548-558.	0.8	10
82	Reply letter to Jinnah "Locus pocus―and Albanese "Complex dystonia is not a category in the new 2013 consensus classification― Necessary evolution, no magic!. Movement Disorders, 2016, 31, 1760-1762.	2.2	1
83	Standardized Assessment of Hereditary Ataxia Patients in Clinical Studies. Movement Disorders Clinical Practice, 2016, 3, 230-240.	0.8	13
84	A <scp><i>LRSAM1</i></scp> mutation links Charcot–Marie–Tooth type 2 to <scp>P</scp> arkinson's disease. Annals of Clinical and Translational Neurology, 2016, 3, 146-149.	1.7	25
85	Peripheral Neuropathy in Spinocerebellar Ataxia Type 1, 2, 3, and 6. Cerebellum, 2016, 15, 165-173.	1.4	54
86	A Positive †Pointing Test†in a Parkinson†S Disease Patient. Journal of Parkinson's Disease, 2015, 5, 727-729.	1.5	0
87	De novo gain-of-function and loss-of-function mutations of <i>SCN8A</i> ii>in patients with intellectual disabilities and epilepsy. Journal of Medical Genetics, 2015, 52, 330-337.	1.5	124
88	A single session of cerebellar theta burst stimulation does not alter writing performance in writer's cramp. Brain, 2015, 138, e355-e355.	3.7	15
89	Differential optimal dopamine levels for set-shifting and working memory in Parkinson's disease. Neuropsychologia, 2015, 77, 42-51.	0.7	41
90	The preclinical stage of spinocerebellar ataxias. Neurology, 2015, 85, 96-103.	1.5	101

#	Article	lF	Citations
91	BDNF polymorphism associates with decline in set shifting in Parkinson's disease. Neurobiology of Aging, 2015, 36, 1605.e1-1605.e6.	1.5	36
92	Functional effects of botulinum toxin type-A treatment and subsequent stretching of spastic calf muscles: A study in patients with hereditary spastic paraplegia. Journal of Rehabilitation Medicine, 2015, 47, 147-153.	0.8	27
93	Reliability and Validity of the Range of Motion Scale (ROMS) in Patients with Abnormal Postures. Pain Medicine, 2015, 16, 488-493.	0.9	4
94	First de novo KCND3 mutation causes severe Kv4.3 channel dysfunction leading to early onset cerebellar ataxia, intellectual disability, oral apraxia and epilepsy. BMC Medical Genetics, 2015, 16, 51.	2.1	46
95	Recessive mutations in POLR1C cause a leukodystrophy by impairing biogenesis of RNA polymerase III. Nature Communications, 2015, 6, 7623.	5.8	127
96	Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study. Lancet Neurology, The, 2015, 14, 1101-1108.	4.9	213
97	Altered striatal and pallidal connectivity in cervical dystonia. Brain Structure and Function, 2015, 220, 513-523.	1.2	43
98	Dynamic cortical gray matter volume changes after botulinum toxin in cervical dystonia. Neurobiology of Disease, 2015, 73, 327-333.	2.1	24
99	Functional Analysis Helps to Define KCNC3 Mutational Spectrum in Dutch Ataxia Cases. PLoS ONE, 2015, 10, e0116599.	1.1	26
100	StartReact Restores Reaction Time in HSP: Evidence for Subcortical Release of a Motor Program. Journal of Neuroscience, 2014, 34, 275-281.	1.7	75
101	Language impairment in cerebellar ataxia. Movement Disorders, 2014, 29, 1307-1312.	2.2	8
102	A novel <i>KCNA1</i> mutation causing episodic ataxia type I. Muscle and Nerve, 2014, 50, 289-291.	1.0	15
103	A Gait Paradigm Reveals Different Patterns of Abnormal Cerebellar Motor Learning in Primary Focal Dystonias. Cerebellum, 2014, 13, 760-766.	1.4	32
104	The clinical utility of botulinum toxin injections targeted at the motor endplate zone in cervical dystonia. European Journal of Neurology, 2014, 21, 1486.	1.7	23
105	<scp>EFNS</scp> / <scp>ENS</scp> Consensus on the diagnosis and management of chronic ataxias in adulthood. European Journal of Neurology, 2014, 21, 552-562.	1.7	79
106	Cognitive impairment in "Other―movement disorders: Hidden defects and valuable clues. Movement Disorders, 2014, 29, 694-703.	2.2	14
107	Prediction of the age at onset in spinocerebellar ataxia type 1, 2, 3 and 6. Journal of Medical Genetics, 2014, 51, 479-486.	1.5	85
108	Drug-Induced Cerebellar Ataxia: A Systematic Review. CNS Drugs, 2014, 28, 1139-1153.	2.7	57

#	Article	IF	CITATIONS
109	Modulation of the age at onset in spinocerebellar ataxia by CAG tracts in various genes. Brain, 2014, 137, 2444-2455.	3.7	144
110	Normal eyeblink classical conditioning in patients with fixed dystonia. Experimental Brain Research, 2014, 232, 1805-9.	0.7	6
111	Beta-propeller protein-associated neurodegeneration (BPAN), a rare form of NBIA: Novel mutations and neuropsychiatric phenotype in three adult patients. Parkinsonism and Related Disorders, 2014, 20, 332-336.	1.1	42
112	Gait adaptability training improves obstacle avoidance and dynamic stability in patients with cerebellar degeneration. Gait and Posture, 2014, 40, 247-251.	0.6	52
113	Serum angiogenin levels are elevated in ALS, but not Parkinson's disease: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1439-1440.	0.9	11
114	Exome Sequencing Extends the Phenotypic Spectrum for ABHD12 Mutations. Ophthalmology, 2014, 121, 1620-1627.	2.5	44
115	The effectiveness of allied health care in patients with ataxia: a systematic review. Journal of Neurology, 2014, 261, 251-258.	1.8	66
116	Writer's cramp: Increased dorsal premotor activity during intended writing. Human Brain Mapping, 2013, 34, 613-625.	1.9	39
117	Inhibition of the dorsal premotor cortex does not repair surround inhibition in writer's cramp patients. Experimental Brain Research, 2013, 225, 85-92.	0.7	14
118	Effects of acetyl-dl-leucine in patients with cerebellar ataxia: a case series. Journal of Neurology, 2013, 260, 2556-2561.	1.8	89
119	Mechanisms of postural instability in hereditary spastic paraplegia. Journal of Neurology, 2013, 260, 2387-2395.	1.8	26
120	Pure adult-onset Spastic Paraplegia caused by a novel mutation in the KIAA0196 (SPG8) gene. Journal of Neurology, 2013, 260, 1765-1769.	1.8	37
121	POLG mutation presenting with late-onset jerky torticollis. Journal of Neurology, 2013, 260, 903-905.	1.8	4
122	Physiotherapy in Degenerative Cerebellar Ataxias: Utilisation, Patient Satisfaction, and Professional Expertise. Cerebellum, 2013, 12, 841-847.	1.4	24
123	Genetic Variation in Ataxia Gene ATXN7 Influences Cerebellar Grey Matter Volume in Healthy Adults. Cerebellum, 2013, 12, 390-395.	1.4	5
124	A Post-Hoc Comparison of the Utility of Sanger Sequencing and Exome Sequencing for the Diagnosis of Heterogeneous Diseases. Human Mutation, 2013, 34, 1721-1726.	1.1	303
125	Does calf muscle spasticity contribute to postural imbalance? A study in persons with pure hereditary spastic paraparesis. Gait and Posture, 2013, 38, 304-309.	0.6	18
126	Cervical dystonia and genetic common variation in the dopamine pathway. Parkinsonism and Related Disorders, 2013, 19, 346-349.	1.1	10

#	Article	IF	CITATIONS
127	Mutational analysis of TARDBP in Parkinson's disease. Neurobiology of Aging, 2013, 34, 1517.e1-1517.e3.	1.5	3
128	Promotion of physical activity and fitness in sedentary patients with Parkinson's disease: randomised controlled trial. BMJ, The, 2013, 346, f576-f576.	3.0	123
129	Genotype-specific patterns of atrophy progression are more sensitive than clinical decline in SCA1, SCA3 and SCA6. Brain, 2013, 136, 905-917.	3.7	128
130	Rapidly deteriorating course in Dutch hereditary spastic paraplegia type 11 patients. European Journal of Human Genetics, 2013, 21, 1312-1315.	1.4	22
131	A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. Human Molecular Genetics, 2013, 22, 1039-1049.	1.4	122
132	Is TOR1A a risk factor in adultâ€onset primary torsion dystonia?. Movement Disorders, 2013, 28, 827-831.	2.2	14
133	Autosomal Recessive Spinocerebellar Ataxia 7 (SCAR7) is Caused by Variants in <i>TPP1</i> , The Gene Involved in Classic Late-Infantile Neuronal Ceroid Lipofuscinosis 2 Disease (CLN2 Disease). Human Mutation, 2013, 34, 706-713.	1.1	70
134	Movement disorders in GLUT1 deficiency syndrome respond to the modified Atkins diet. Movement Disorders, 2013, 28, 1439-1442.	2.2	47
135	Phenotypic variability in a dystonia family with mutations in the manganese transporter gene. Movement Disorders, 2013, 28, 685-686.	2.2	9
136	A de novo SCA14 mutation in an isolated case of lateâ€onset cerebellar ataxia. Movement Disorders, 2013, 28, 1902-1903.	2.2	7
137	Early onset dystonia and parkinsonism with abnormal globus pallidal signal in MRI: A diagnostic challenge. Movement Disorders, 2013, 28, 2035-2036.	2.2	5
138	Task-Free Functional MRI in Cervical Dystonia Reveals Multi-Network Changes That Partially Normalize with Botulinum Toxin. PLoS ONE, 2013, 8, e62877.	1.1	112
139	Genotype–phenotype correlations in spastic paraplegia type 7: a study in a large Dutch cohort. Brain, 2012, 135, 2994-3004.	3.7	107
140	Phenotypes and genetic architecture of focal primary torsion dystonia. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 1006-1011.	0.9	22
141	Compensatory Activity in the Extrastriate Body Area of Parkinson's Disease Patients. Journal of Neuroscience, 2012, 32, 9546-9553.	1.7	66
142	Cerebellar Cognitive Affective Syndrome and Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay: A Report of Two Male Sibs. Psychopathology, 2012, 45, 193-199.	1.1	19
143	Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism. Brain, 2012, 135, 3687-3698.	3.7	33
144	Current and future medical treatment in primary dystonia. Therapeutic Advances in Neurological Disorders, 2012, 5, 221-240.	1.5	29

#	Article	IF	Citations
145	Mutations in DDHD2, Encoding an Intracellular Phospholipase A1, Cause a Recessive Form of Complex Hereditary Spastic Paraplegia. American Journal of Human Genetics, 2012, 91, 1073-1081.	2.6	159
146	Mutations in potassium channel $\langle i \rangle$ kcnd3 $\langle i \rangle$ cause spinocerebellar ataxia type 19. Annals of Neurology, 2012, 72, 870-880.	2.8	121
147	A practical approach to late-onset cerebellar ataxia: putting the disorder with lack of order into order. Practical Neurology, 2012, 12, 14-24.	0.5	28
148	Cervical dystonia after ear surgery. Parkinsonism and Related Disorders, 2012, 18, 669-671.	1.1	1
149	Reviewing the genetic causes of spastic-ataxias. Neurology, 2012, 79, 1507-1514.	1.5	71
150	Reduced parietal connectivity with a premotor writing area in writer's cramp. Movement Disorders, 2012, 27, 1425-1431.	2.2	69
151	Cerebellar theta burst stimulation impairs eyeblink classical conditioning. Journal of Physiology, 2012, 590, 887-897.	1.3	55
152	Hereditary spastic paraplegia caused by a mutation in the VCP gene. Brain, 2012, 135, e223-e223.	3.7	57
153	Improving the diagnostic accuracy in parkinsonism: a three-pronged approach. Practical Neurology, 2012, 12, 77-87.	0.5	32
154	Angiogenin, a piece of the complex puzzle of neurodegeneration. Annals of Neurology, 2012, 71, 727-728.	2.8	1
155	Republished: A practical approach to late-onset cerebellar ataxia: putting the disorder with lack of order into order. Postgraduate Medical Journal, 2012, 88, 407-417.	0.9	0
156	Spinocerebellar Ataxia Types 1, 2, 3 and 6: the Clinical Spectrum of Ataxia and Morphometric Brainstem and Cerebellar Findings. Cerebellum, 2012, 11, 155-166.	1.4	74
157	Mutations in SLC30A10 Cause Parkinsonism and Dystonia with Hypermanganesemia, Polycythemia, and Chronic Liver Disease. American Journal of Human Genetics, 2012, 90, 467-477.	2.6	343
158	Presence of ATM protein and residual kinase activity correlates with the phenotype in ataxia-telangiectasia: A genotype-phenotype study. Human Mutation, 2012, 33, 561-571.	1.1	129
159	Reâ€emergent tremor in a dystonic SWEDD case. Movement Disorders, 2012, 27, 462-463.	2.2	12
160	Association of BDNF Met66Met polymorphism with arm tremor in cervical dystonia. Movement Disorders, 2012, 27, 796-797.	2.2	13
161	How might physical activity benefit patients with Parkinson disease?. Nature Reviews Neurology, 2011, 7, 528-534.	4.9	227
162	A distinctive pattern of cortical excitability in patients with the syndrome of dystonia and cerebellar ataxia. Clinical Neurophysiology, 2011, 122, 1816-1819.	0.7	10

#	Article	IF	CITATIONS
163	Ataxia telangiectasia: The consequences of a delayed diagnosis. Radiotherapy and Oncology, 2011, 99, 97-98.	0.3	14
164	Genome-wide association study confirms extant PD risk loci among the Dutch. European Journal of Human Genetics, 2011, 19, 655-661.	1.4	164
165	Postural deformities in Parkinson's disease. Lancet Neurology, The, 2011, 10, 538-549.	4.9	423
166	Breakpoint mapping of 13 large parkin deletions/duplications reveals an exon 4 deletion and an exon 7 duplication as founder mutations. Neurogenetics, 2011, 12, 263-271.	0.7	16
167	Cerebellar brain inhibition is decreased in active and surround muscles at the onset of voluntary movement. Experimental Brain Research, 2011, 209, 437-442.	0.7	39
168	Movement disorders in spinocerebellar ataxias. Movement Disorders, 2011, 26, 792-800.	2.2	124
169	Depression comorbidity in spinocerebellar ataxia. Movement Disorders, 2011, 26, 870-876.	2.2	69
170	Kleefstra syndrome in three adult patients: Further delineation of the behavioral and neurological phenotype shows aspects of a neurodegenerative course. American Journal of Medical Genetics, Part A, 2011, 155, 2409-2415.	0.7	38
171	Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Annals of Neurology, 2011, 70, 964-973.	2.8	168
172	Genetics of the Dominant Ataxias. Seminars in Neurology, 2011, 31, 461-469.	0.5	33
173	Patients with primary cervical dystonia have evidence of discrete deficits in praxis. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 615-619.	0.9	7
174	Prodynorphin Mutations Cause the Neurodegenerative Disorder Spinocerebellar Ataxia Type 23. American Journal of Human Genetics, 2010, 87, 593-603.	2.6	99
175	Targeted Next-Generation Sequencing of a 12.5 Mb Homozygous Region Reveals ANO10 Mutations in Patients with Autosomal-Recessive Cerebellar Ataxia. American Journal of Human Genetics, 2010, 87, 813-819.	2.6	125
176	Falls in Spinocerebellar Ataxias: Results of the EuroSCA Fall Study. Cerebellum, 2010, 9, 232-239.	1.4	59
177	Selfâ€rated health status in spinocerebellar ataxiaâ€"Results from a European multicenter study. Movement Disorders, 2010, 25, 587-595.	2.2	74
178	Nonmotor symptoms in <i>Parkin</i> geneâ€related parkinsonism. Movement Disorders, 2010, 25, 1279-1284.	2.2	31
179	Pallidopyramidal disease: A misnomer?. Movement Disorders, 2010, 25, 1109-1115.	2.2	9
180	DYT6 dystonia: Mutation screening, phenotype, and response to deep brain stimulation. Movement Disorders, 2010, 25, 2420-2427.	2.2	95

#	Article	IF	CITATIONS
181	The clinical approach to movement disorders. Nature Reviews Neurology, 2010, 6, 29-37.	4.9	166
182	Validation of a dystonia screening questionnaire: Testing in a cohort of mixed neurological disorders. Parkinsonism and Related Disorders, 2010, 16, 620-622.	1.1	2
183	Visualization, quantification and correlation of brain atrophy with clinical symptoms in spinocerebellar ataxia types 1, 3 and 6. Neurolmage, 2010, 49, 158-168.	2.1	162
184	Repetitive transcranial magnetic stimulation for levodopaâ€induced dyskinesias in Parkinson's disease. Movement Disorders, 2009, 24, 246-253.	2.2	75
185	Atypical dystonic shoulder movements following neuralgic amyotrophy. Movement Disorders, 2009, 24, 293-296.	2.2	12
186	Paramedical treatment in primary dystonia: A systematic review. Movement Disorders, 2009, 24, 2187-2198.	2.2	61
187	Seipin/BSCL2 mutation screening in sporadic adult-onset upper motor neuron syndromes. Journal of Neurology, 2009, 256, 824-826.	1.8	4
188	ARSACS in the Dutch population: a frequent cause of early-onset cerebellar ataxia. Neurogenetics, 2008, 9, 207-214.	0.7	132
189	Cortical excitability is abnormal in patients with the "fixed dystonia―syndrome. Movement Disorders, 2008, 23, 646-652.	2.2	111
190	Antineuronal antibodies in Parkinson's disease. Movement Disorders, 2008, 23, 958-963.	2.2	17
191	Alexander disease causing hereditary lateâ€onset ataxia with only minimal white matter changes: A report of two sibs. Movement Disorders, 2008, 23, 1613-1615.	2.2	7
192	Early symptoms in spinocerebellar ataxia type 1, 2, 3, and 6. Movement Disorders, 2008, 23, 2232-2238.	2.2	125
193	Screening of hereditary spastic paraplegia patients for alterations at NIPA1 mutational hotspots. Journal of the Neurological Sciences, 2008, 268, 131-135.	0.3	17
194	REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31. Brain, 2008, 131, 1078-1086.	3.7	163
195	There might be more to SPG4!. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 80, 357-357.	0.9	1
196	Paraneoplastic Cerebellar Ataxia due to Burnt-Out Testicular Germ Cell Tumour?. European Neurology, 2007, 57, 178-181.	0.6	10
197	Persisting hyperekplexia after idiopathic, self-limiting brainstem encephalopathy. Movement Disorders, 2007, 22, 1017-1020.	2.2	8
198	PRKCG mutation (SCA-14) causing a Ramsay Hunt phenotype. Movement Disorders, 2007, 22, 1024-1026.	2.2	19

#	Article	IF	CITATIONS
199	The phenomenon of disproportionate antecollis in Parkinson's disease and multiple system atrophy. Movement Disorders, 2007, 22, 2325-2331.	2.2	55
200	Neurological gait disorders in elderly people: clinical approach and classification. Lancet Neurology, The, 2007, 6, 63-74.	4.9	399
201	Postural responses to multidirectional stance perturbations in cerebellar ataxia. Experimental Neurology, 2006, 202, 21-35.	2.0	82
202	BSCL2 mutations in two Dutch families with overlapping Silver syndrome-distal hereditary motor neuropathy. Neuromuscular Disorders, 2006, 16, 122-125.	0.3	29
203	Neurophysiologic Studies in Early-Onset Cerebellar Ataxia. Journal of Clinical Neurophysiology, 2006, 23, 381-387.	0.9	3
204	Reliability and validity of the International Cooperative Ataxia Rating Scale: A study in 156 spinocerebellar ataxia patients. Movement Disorders, 2006, 21, 699-704.	2.2	150
205	NovelPRKCG/SCA14 mutation in a Dutch spinocerebellar ataxia family: Expanding the phenotype. Movement Disorders, 2006, 21, 1025-1028.	2.2	42
206	The syndrome of (predominantly cervical) dystonia and cerebellar ataxia: new cases indicate a distinct but heterogeneous entity. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 774-775.	0.9	19
207	Recent Advances in Hereditary Spinocerebellar Ataxias. Journal of Neuropathology and Experimental Neurology, 2005, 64, 171-180.	0.9	39
208	Clinical, psychological, and genetic characteristics of spinocerebellar ataxia type 19 (SCA19). Cerebellum, 2005, 4, 51-54.	1.4	29
209	Age at onset variance analysis in spinocerebellar ataxias: A study in a Dutch-French cohort. Annals of Neurology, 2005, 57, 505-512.	2.8	95
210	Falls in degenerative cerebellar ataxias. Movement Disorders, 2005, 20, 497-500.	2.2	101
211	Trunk sway in patients with spinocerebellar ataxia. Movement Disorders, 2005, 20, 1006-1013.	2.2	76
212	Gly118Asp is a SCA14 founder mutation in the Dutch ataxia population. Human Genetics, 2005, 117, 88-91.	1.8	30
213	Spinocerebellar ataxia type 14. Neurology, 2005, 64, 1113-1114.	1.5	4
214	Spinocerebellar Ataxia and Peripheral Neuropathy—Reply. Archives of Neurology, 2004, 61, 1626.	4.9	0
215	Peripheral Nerve Involvement in Spinocerebellar Ataxias. Archives of Neurology, 2004, 61, 257.	4.9	101
216	SCA19 and SCA22: evidence for one locus with a worldwide distribution. Brain, 2004, 127, 6E-6.	3.7	33

#	Article	IF	CITATIONS
217	Neuromuscular transmission in SCA6. Annals of Neurology, 2004, 55, 451-452.	2.8	9
218	Concomitant dermatomyositis and myasthenia gravis presenting with respiratory insufficiency. Muscle and Nerve, 2002, 25, 293-296.	1.0	23
219	Paroxysmal Leg Weakness and Hearing Loss in a Patient with Subarachnoid Hemorrhage. European Neurology, 2000, 44, 186-187.	0.6	3
220	Phenomenology, classification, and diagnostic approach to patients with movement disorders. , 0, , 1-15.		0